Keck School Faculty

Evanthia Roussos Torres

Evanthia Roussos Torres

Assistant Professor of Medicine
NOR 6412 NTT Health Sciences Campus Los Angeles

Clocking cancer: the circadian clock as a target in cancer therapy Oncogene. 2021 05; 40(18):3187-3200. . View in PubMed

Adopting an alternative structure for clinical trials in immunotherapy Expert Rev Anticancer Ther. 2021 04; 21(4):373-375. . View in PubMed

Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response Front Mol Biosci. 2021; 8:674558. . View in PubMed

Evaluating the impact of age on immune checkpoint therapy biomarkers Cell Rep. 2021 08 24; 36(8):109599. . View in PubMed

Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) Clin Cancer Res. 2021 11 01; 27(21):5828-5837. . View in PubMed

Phenotypic shifts of tumor associated macrophages and STAT3 mediated suppression of myeloid derived suppressor cells drive sensitization of HER2+ tumor immunity bioRxiv. 2021. . View in PubMed

Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach JCO Oncol Pract. 2020 Oct; 16(10):665-674. . View in PubMed

Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-16. . View in PubMed

Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide Oncoimmunology. 2020 05 14; 9(1):1760685. . View in PubMed

Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors Front Bioeng Biotechnol. 2020; 8:141. . View in PubMed

A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity Cancer Immunol Res. 2019 03; 7(3):428-442. . View in PubMed

Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data Cancer Res. 2019 10 01; 79(19):5102-5112. . View in PubMed

Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs Cancer Immunol Res. 2018 12; 6(12):1561-1577. . View in PubMed

Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer Current Breast Cancer Reports. 2018. . View in PubMed

N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors J Cell Sci. 2012 Feb 01; 125(Pt 3):724-34. . View in PubMed

Setup and use of a two-laser multiphoton microscope for multichannel intravital fluorescence imaging Nat Protoc. 2011 Sep 08; 6(10):1500-20. . View in PubMed

Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM Clin Exp Metastasis. 2011 Aug; 28(6):515-27. . View in PubMed

Chemotaxis in cancer Nat Rev Cancer. 2011 Jul 22; 11(8):573-87. . View in PubMed

Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer J Cell Sci. 2011 Jul 01; 124(Pt 13):2120-31. . View in PubMed

AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment Cancer Res. 2010 Oct 01; 70(19):7360-4. . View in PubMed

Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors Breast Cancer Res. 2010; 12(6):R101. . View in PubMed

Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase Cancer Res. 2009 Dec 01; 69(23):8868-76. . View in PubMed

A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis Dev Cell. 2008 Dec; 15(6):813-28. . View in PubMed

Genetic analysis of the diabetes-prone C57BLKS/J mouse strain reveals genetic contribution from multiple strains Biochim Biophys Acta. 2006 Apr; 1762(4):440-6. . View in PubMed

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents Clin Cancer Res. 2003 Mar; 9(3):1136-44. . View in PubMed

Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma Cancer Genet Cytogenet. 2002 Aug; 137(1):43-8. . View in PubMed

Dr. Roussos Torres received a BS in Microbiology, Immunology and Molecular Genetics and a BA in World Arts and Cultures with a concentration in Dance from the University of California at Los Angeles (UCLA). She then went on to receive her combined MD/PhD from the Medical Scientist Training Program at the Albert Einstein College of Medicine in New York. She then completed her internal medicine residency at the Hospital of the University of Pennsylvania. She began her hematology/ oncology fellowship training at the University of Pennsylvania and following the completion of her major clinical requirements, she transferred to Johns Hopkins University to pursue her research interests in cancer immunology under the mentorship of Dr. Elizabeth Jaffee. Dr. Roussos Torres graduated from fellowship and began her faculty career as an Assistant Professor at Johns Hopkins University and is now an Assistant Professor at the University of Southern California she leads her own lab and works collaboratively with other physicians and physician scientists to continue her work in immune-oncology with a specific interest in breast cancer.

Dr. Roussos Torres is very passionate about her research as well as her care of patients with cancer and training of the fellows to become compassionate and knowledgeable physicians. She is driven to make memorable contributions to the field of cancer research given her personal experience advocating for her mother who died from metastatic breast cancer in 2016. Dr. Roussos Torres felt passionate about having an impact on the field of breast cancer prior to her mother’s diagnosis but learning about the devastation of metastatic disease as the family member of a patient provided a different perspective and drive for novel treatment options.

Dr. Roussos Torres loves her work but also prioritizes her family life; her husband Dr. Stephen Torres is an orthopedic surgeon, specializing in sports medicine and together they have three sons, Owen (6 years old), James (4 years old) and Luke (2 year old) who fill their life with joy and make every day a wonder! The Torres family also has two Chesapeake Bay retrievers, Jackson (10 years old) and Emma (7 years old) who greatly contribute to our active lifestyle! Dr. Roussos Torres enjoys traveling, eating out at new restaurants and road biking! Dr. Roussos Torres grew up in Santa Monica and is so happy to have returned to Southern California where she and her husband can raise their family near her siblings, their families, and her father who still resides here.

Laboratory website:

Publications library:
sc ctsi logoPowered by SC CTSI